Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Why this topic
- Drug formulation: definition
- Criteria for a ‘useful’ formulation
- Drug formulations: by route
- Drug formulations: solid formulations (tablets and enteric-coated tablets)
- Solid formulations (controlled release tablets and capsules)
- Semi-solid formulations
- Parenteral formulations
- Extemporaneous formulations
- Take-home messages
Topics Covered
- Drug formulations
- Criteria for ‘useful’ formulation
- Solid drug formulations
- Semi-solid drug formulations
- Parenteral drug preparations
- Extemporaneous drug formulations
Talk Citation
Allegaert, K. (2024, October 31). Drug formulations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 13, 2024, from https://doi.org/10.69645/SQUG7671.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose. However, off label use of medicines is discussed.
Other Talks in the Series: Key Concepts: Fundamentals of Pharmacology
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to the short lecture on
drug formulations.
I'm Karel Allegaert.
I'm a clinical
pharmacologist working at
KU Leuven; and happy to
introduce you to this topic.
0:14
Why would we bother
about this topic?
It's because different
formulations will result in
different exposure
time profiles and
related to that, potential
effects or side effects.
For specific details on that,
I refer to the short lecture
on pharmacokinetics.
If you compare IV formulations,
or intravenous formulations,
to oral formulations
or to other routes,
it's quite obvious
that related to
absorption, the pattern of
a concentration over
time will change.
But even within an
oral formulation,
you could compare a
slow release versus
a general or a common
standard formulation.
Formulations contain
also other compounds
besides what we consider the
drug (active compounds).
This may have to do
with excipients,
may have to do with
taste masking,
or may have to do
with preservatives.
Excipients are commonly
used to improve
the solubility of a formulation,
taste masking is all
about palatability,
and preservatives,
obviously, will
improve the shelf
life of a given drug.
Selection of a formulation
should, obviously,
be based on patient
preferences and needs.
It may have to do with age or
with disease-related
characteristics.
For instance, swallowing issues.
Then finally, I would like to
highlight extemporaneous
formulations,
as this is still commonly
used for specific needs.